X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (22) 22
oncology (15) 15
nivolumab (11) 11
humans (9) 9
immunotherapy (8) 8
lung cancer (8) 8
article (5) 5
cancer (5) 5
open-label (5) 5
antibodies, monoclonal - therapeutic use (4) 4
antineoplastic agents - therapeutic use (4) 4
chemotherapy (4) 4
docetaxel (4) 4
ipilimumab (4) 4
mutation (4) 4
pembrolizumab (4) 4
respiratory system (4) 4
abridged index medicus (3) 3
adverse events (3) 3
aged (3) 3
cancer therapies (3) 3
chemistry, medicinal (3) 3
female (3) 3
immune checkpoint inhibitors (3) 3
lymphocytes (3) 3
male (3) 3
neoplasms - immunology (3) 3
non-small cell lung cancer (3) 3
safety (3) 3
aged, 80 and over (2) 2
analysis (2) 2
anti-pd-1 (2) 2
anti-pd-l1 antibody (2) 2
antibodies, monoclonal - adverse effects (2) 2
antibody (2) 2
antineoplastic agents - adverse effects (2) 2
apoptosis (2) 2
b7-h1 antigen - antagonists & inhibitors (2) 2
biomarkers (2) 2
biopsy (2) 2
blockade (2) 2
carcinoma, non-small-cell lung - drug therapy (2) 2
carcinoma, non-small-cell lung - immunology (2) 2
carcinoma, non-small-cell lung - pathology (2) 2
carcinoma, non-small-cell lung - therapy (2) 2
care and treatment (2) 2
checkpoint blockade (2) 2
clinical activity (2) 2
clinical trials as topic (2) 2
clonal hematopoiesis (2) 2
dna (2) 2
drug discovery (2) 2
drug therapy (2) 2
elderly (2) 2
enhancement (2) 2
evolution (2) 2
genetic aspects (2) 2
genomes (2) 2
genomics (2) 2
immune checkpoint blockade (2) 2
immunology (2) 2
immunosenescence (2) 2
immunotherapy - methods (2) 2
lung cancer, non-small cell (2) 2
lung neoplasms - drug therapy (2) 2
lung neoplasms - immunology (2) 2
lung neoplasms - pathology (2) 2
lung neoplasms - therapy (2) 2
lymphocytes t (2) 2
melanoma (2) 2
metformin (2) 2
middle aged (2) 2
multicenter (2) 2
mutations (2) 2
neoadjuvant therapy (2) 2
neoantigens (2) 2
neoplasms - therapy (2) 2
neoplasms. tumors. oncology. including cancer and carcinogens (2) 2
non-small cell lung carcinoma (2) 2
nsclc (2) 2
patients (2) 2
peptides (2) 2
phosphodiesterase inhibitors - pharmacology (2) 2
pneumonitis (2) 2
review article (2) 2
solid tumors (2) 2
t cells (2) 2
t-cells (2) 2
therapy (2) 2
treatment outcome (2) 2
tumors (2) 2
1st-line treatment (1) 1
aberrations (1) 1
academic medical centers (1) 1
academic training (1) 1
acute interstitial nephritis (1) 1
acute kidney injury (1) 1
acute kidney injury - blood (1) 1
acute kidney injury - chemically induced (1) 1
acute kidney injury - pathology (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature Reviews Clinical Oncology, ISSN 1759-4774, 09/2019
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 09/2019, Volume 37, Issue 27_suppl, pp. 51 - 51
51 Background: ASCO guidelines recommend palliative care (PC) referral for patients with advanced or metastatic cancer. Despite this, implementation has... 
Journal Article
Cancer Journal (United States), ISSN 1528-9117, 07/2017, Volume 23, Issue 4, pp. 219 - 222
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 8_suppl, pp. 84 - 84
84 Background: Anti-PD-1/PD-L1 immune checkpoint inhibitors (ICIs) for cancer may cause immune-related adverse events (irAEs). Large clinical trials and... 
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 12/2018, Volume 13, Issue 12, pp. 1930 - 1939
Checkpoint inhibitor pneumonitis (CIP) is an immune-related adverse event that can occur after initiation of anti–programmed death 1/programmed death ligand 1... 
Checkpoint inhibitor pneumonitis | Checkpoint inhibitors | Immune-related adverse events | NSCLC | Immunotherapy | PEMBROLIZUMAB | ONCOLOGY | RESPIRATORY SYSTEM | INHIBITORS | NIVOLUMAB | DOCETAXEL | ADVERSE EVENTS
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2018, Volume 36, Issue 5_suppl, pp. 138 - 138
138 Background: Immune checkpoint inhibitors (ICIs) are anti-cancer agents now in routine clinical practice, and may cause immune-related adverse events... 
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 03/2019, Volume 37, Issue 8_suppl, pp. 105 - 105
105 Background: The use of immune targeted agents for NSCLC has improved outcomes for patients (pts) with metastatic disease. Biomarkers such as the... 
Journal Article
ONCOLOGY (United States), ISSN 0890-9091, 08/2016, Volume 30, Issue 8, pp. 713 - 721
Immune checkpoint inhibition using targeted monoclonal antibodies is changing the treatment paradigm for lung cancer. Approval by the US Food and Drug... 
MULTICENTER | ANTI-PD-L1 ANTIBODY | SOLID TUMORS | ONCOLOGY | SAFETY | IMMUNOTHERAPY | DOUBLE-BLIND | PHASE-II | ANTITUMOR IMMUNITY | CELL | IPILIMUMAB
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 03/2019, Volume 14, Issue 3, pp. 494 - 502
With increasing use of immune checkpoint inhibitors (ICIs) for advanced NSCLC, there is increasing recognition of immune-related adverse events associated with... 
ONCOLOGY | NIVOLUMAB | RESPIRATORY SYSTEM | DOCETAXEL
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 05/2018, Volume 378, Issue 21, pp. 1976 - 1986
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, p. S893
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S893 - S893
Journal Article
Journal for ImmunoTherapy of Cancer, ISSN 2051-1426, 02/2019, Volume 7, Issue 1, pp. 40 - 8
BackgroundSeveral predictive biomarkers are currently approved or are under investigation for the selection of patients for checkpoint blockade. Tumor PD-L1... 
Neoantigens | T cells | Checkpoint blockade | Oncogene | Predictive biomarkers | DOMAIN | PD-1 BLOCKADE | BRAF | IMMUNOLOGY | CANCER | TUMORS | ONCOLOGY | AFFINITY | AKT1 | MUTATIONS | BINDING | Medical research | Immunotherapy | Colorectal cancer | Medicine, Experimental | Genetic aspects | Lung cancer, Non-small cell | Tumors | Lymphocytes | Lung cancer | Genomics | Melanoma | Biomarkers | Ligands | Mutation | Patients | Cancer therapies
Journal Article
JOURNAL OF ONCOLOGY PRACTICE, ISSN 1554-7477, 09/2019, Volume 15, Issue 9, pp. 494 - 494
PURPOSE: Immune checkpoint inhibitors (ICIs) cause immune-related adverse events (irAEs). The proportion of patients who are hospitalized for irAEs and their... 
THERAPY | ONCOLOGY | SAFETY | ANTIBODY | NIVOLUMAB | BLOCKADE | IPILIMUMAB
Journal Article
Clinical Lung Cancer, ISSN 1525-7304, 07/2019, Volume 20, Issue 4, pp. e470 - e479
To investigate the relationship between radiotherapy (RT), in particular chest RT, and development of immune-related (IR) pneumonitis in non–small-cell lung... 
Pembrolizumab | Pneumonitis | Anti–PD-1/PD-L1 therapy | Nivolumab | Radiation | DENSITY | ONCOLOGY | Anti-PD-1/PD-L1 therapy | TIME | ANTI-PD-1 | OUTCOMES
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.